Marginal Zone Lymphoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys, Beijing Mabworks Biotec

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Marginal Zone Lymphoma pipeline constitutes 50+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Marginal Zone Lymphoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Marginal Zone Lymphoma Market.

The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Marginal Zone Lymphoma Pipeline Report: https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Marginal Zone Lymphoma treatment therapies with a considerable amount of success over the years.
• Marginal Zone Lymphoma companies working in the treatment market are Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others, are developing therapies for the Marginal Zone Lymphoma treatment
• Emerging Marginal Zone Lymphoma therapies in the different phases of clinical trials are- AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others are expected to have a significant impact on the Marginal Zone Lymphoma market in the coming years.
• In May 2024, ADC Therapeutics SA (NYSE: ADCT) has disclosed that preliminary findings from an investigator-launched Phase 2 clinical study assessing ZYNLONTA® (loncastuximab tesirine-lpyl) revealed a significant response rate among patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
• In April 2024, Verismo Therapeutics, a clinical-stage CAR T company pioneering the innovative KIR-CAR platform technology, has announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its Phase 1 clinical trial of SynKIR™-310. This trial aims to evaluate the efficacy of SynKIR™-310 in treating relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), which includes Diffuse Large B Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL).
• In March 2024, InnoCare Pharma has obtained approval for an investigational new drug application to commence a clinical study evaluating ICP-248 combined with orelabrutinib in China for the treatment of lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
• In August 2022, The first patient in a company-sponsored Phase I/II research assessing a conveniently available, cryopreserved formulation of GDA-201 for the treatment of follicular, diffuse large B cell lymphomas, as well as marginal zone lymphoma or mantle cell lymphoma, has been dosed, according to Gamida Cell.

Marginal Zone Lymphoma Overview
Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma (NHL) that arises from B-cells in the marginal zone of lymphoid tissue. It is characterized by the abnormal growth of these B-cells, leading to the formation of tumors in various organs and tissues, such as the lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT).

Get a Free Sample PDF Report to know more about Marginal Zone Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Marginal Zone Lymphoma Drugs Under Different Phases of Clinical Development Include:
• AS-1763: Carna Biosciences
• Amdizalisib (HMPL689): Hutchmed
• Parsaclisib (IBI376): Incyte/Innovent
• Tafasitamab: MorphoSys/Incyte
• Zanubrutinib: Beigene
• Orelabrutinib: InnoCare Pharma
• Tafasitamab: Incyte Corporation
• MIL62: Beijing Mabworks Biotech Co.
• Zandelisib: MEI Pharma, Inc./Kyowa Kirin
• Loncastuximab: ADC Therapeutics
• LOXO-305: Loxo Oncology
• ADI-001: Adicet Bio
• CDX-1140: Celldex Therapeutics Inc

Marginal Zone Lymphoma Route of Administration
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Marginal Zone Lymphoma Molecule Type
Marginal Zone Lymphoma Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Marginal Zone Lymphoma Pipeline Therapeutics Assessment
• Marginal Zone Lymphoma Assessment by Product Type
• Marginal Zone Lymphoma By Stage and Product Type
• Marginal Zone Lymphoma Assessment by Route of Administration
• Marginal Zone Lymphoma By Stage and Route of Administration
• Marginal Zone Lymphoma Assessment by Molecule Type
• Marginal Zone Lymphoma by Stage and Molecule Type

DelveInsight's Marginal Zone Lymphoma Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Marginal Zone Lymphoma product details are provided in the report. Download the Marginal Zone Lymphoma pipeline report to learn more about the emerging Marginal Zone Lymphoma therapies
https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Marginal Zone Lymphoma Therapeutics Market include:
Key companies developing therapies for Marginal Zone Lymphoma are - Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, and others.

Marginal Zone Lymphoma Pipeline Analysis:
The Marginal Zone Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
• Marginal Zone Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Marginal Zone Lymphoma drugs and therapies
https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Marginal Zone Lymphoma Pipeline Market Drivers
• Increasing Prevalence, increased research and development are some of the important factors that are fueling the Marginal Zone Lymphoma Market.

Marginal Zone Lymphoma Pipeline Market Barriers
• However, therapies with moderately good patient outcomes, long treatment course and other factors are creating obstacles in the Marginal Zone Lymphoma Market growth.

Scope of Marginal Zone Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key Marginal Zone Lymphoma Companies: Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others
• Key Marginal Zone Lymphoma Therapies: AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others
• Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
• Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers

Request for Sample PDF Report for Marginal Zone Lymphoma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Marginal Zone Lymphoma Report Introduction
2. Marginal Zone Lymphoma Executive Summary
3. Marginal Zone Lymphoma Overview
4. Marginal Zone Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Marginal Zone Lymphoma Pipeline Therapeutics
6. Marginal Zone Lymphoma Late Stage Products (Phase II/III)
7. Marginal Zone Lymphoma Mid Stage Products (Phase II)
8. Marginal Zone Lymphoma Early Stage Products (Phase I)
9. Marginal Zone Lymphoma Preclinical Stage Products
10. Marginal Zone Lymphoma Therapeutics Assessment
11. Marginal Zone Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Marginal Zone Lymphoma Key Companies
14. Marginal Zone Lymphoma Key Products
15. Marginal Zone Lymphoma Unmet Needs
16 . Marginal Zone Lymphoma Market Drivers and Barriers
17. Marginal Zone Lymphoma Future Perspectives and Conclusion
18. Marginal Zone Lymphoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Marginal Zone Lymphoma Market https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).

Latest Reports by DelveInsight

Graft Versus Host Disease Market http://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft-versus-host Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Graft-versus-host Disease, historical and forecasted epidemiology as well as the Graft-versus-host Disease market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Implantable Cardioverter Defibrillators Market http://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
DelveInsight's 'Implantable Cardioverter Defibrillators (ICDs) - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Implantable Cardioverter Defibrillators (ICDs) and the historical and forecasted Implantable Cardioverter Defibrillators (ICDs) market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.